J
James R. Berenson
Researcher at Cedars-Sinai Medical Center
Publications - 32
Citations - 5922
James R. Berenson is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Multiple myeloma & Zoledronic acid. The author has an hindex of 19, co-authored 32 publications receiving 5763 citations. Previous affiliations of James R. Berenson include University of California, Los Angeles & Cornell University.
Papers
More filters
Journal ArticleDOI
A phase 2 study of bortezomib in relapsed, refractory myeloma.
Paul G. Richardson,Bart Barlogie,James R. Berenson,Seema Singhal,Sundar Jagannath,D. Irwin,S. Vincent Rajkumar,Gordan Srkalovic,Melissa Alsina,Raymond Alexanian,David S. Siegel,Robert Z. Orlowski,David J. Kuter,Steven Limentani,Stephanie J. Lee,Teru Hideshima,Dixie Lee Esseltine,Michael Kauffman,Julian Adams,David P. Schenkein,Kenneth C. Anderson +20 more
TL;DR: Bortezomib, a member of a new class of anticancer drugs, is active in patients with relapsed multiple myeloma that is refractory to conventional chemotherapy.
Journal ArticleDOI
American Society of Clinical Oncology Clinical Practice Guidelines: The Role of Bisphosphonates in Multiple Myeloma
James R. Berenson,Bruce E. Hillner,Robert A. Kyle,Kenneth C. Anderson,Allan Lipton,Gary C. Yee,J. Sybil Biermann +6 more
TL;DR: Clinical practice guidelines for the use of bisphosphonates in the prevention and treatment of lytic bone disease in multiple myeloma and to determine their respective role relative to other conventional therapies for this condition are determined.
Journal ArticleDOI
Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: A double-blind, randomized dose-response study
James R. Berenson,Lee S. Rosen,Anthony Howell,Lester Porter,Robert E. Coleman,Walter Morley,Robert Dreicer,Steven A. Kuross,Allan Lipton,John J. Seaman +9 more
TL;DR: This study evaluated the dose–response relation for zoledronic acid, a new generation high potency bisphosphonate, given as a 5‐minute infusion in patients with malignant osteolytic disease.
Journal ArticleDOI
Detection and localization of tumor necrosis factor in human atheroma
Peter Barath,Michael C. Fishbein,Jin Cao,James R. Berenson,Richard H. Helfant,James S. Forrester +5 more
TL;DR: Because TNF is known to cause new vessel formation, hemorrhagic necrosis and increased thrombogenicity, it may play a role in the evolution of uncomplicated to complex atheroma.
Journal ArticleDOI
American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer
Bruce E. Hillner,James N. Ingle,James R. Berenson,Nora A. Janjan,Kathy S. Albain,Allan Lipton,Gary Yee,J. Sybil Biermann,Rowan T. Chlebowski,David G. Pfister +9 more
TL;DR: Clinical practice guidelines for the use of bisphosphonates in the prevention and treatment of bone metastases in breast cancer and their role relative to other therapies for this condition are determined.